Next Article in Journal
Trastuzumab in Metastatic Breast Cancer after Complete Remission: An Expensive Commitment for an Entire Life?
Previous Article in Journal
Moving Guidelines into Action: A Report from Cancer Care Ontario’s Event Let’s Get Moving: Exercise and Rehabilitation for Cancer Patients
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Letter

Chemonaïveté in Inoperable Malignant Bowel Obstruction

by
Saber Boutayeb
*,
Ibrahim El Ghissassi
,
Hind Mrabti
and
Hassan Errihani
Department of Medical Oncology, National Institute of Oncology, University Mohammed V, Rabat, Morocco
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2017, 24(1), 75; https://doi.org/10.3747/co.24.3362
Submission received: 6 November 2016 / Revised: 7 December 2016 / Accepted: 8 January 2017 / Published: 1 February 2017

Abstract

We are writing concerning the article titled “Metronomic chemotherapy with 5-fluorouracil and cisplatin for inoperable malignant bowel obstruction because of peritoneal dissemination from gastric cancer” recently published in your journal by Yang et al.[...]

Share and Cite

MDPI and ACS Style

Boutayeb, S.; El Ghissassi, I.; Mrabti, H.; Errihani, H. Chemonaïveté in Inoperable Malignant Bowel Obstruction. Curr. Oncol. 2017, 24, 75. https://doi.org/10.3747/co.24.3362

AMA Style

Boutayeb S, El Ghissassi I, Mrabti H, Errihani H. Chemonaïveté in Inoperable Malignant Bowel Obstruction. Current Oncology. 2017; 24(1):75. https://doi.org/10.3747/co.24.3362

Chicago/Turabian Style

Boutayeb, Saber, Ibrahim El Ghissassi, Hind Mrabti, and Hassan Errihani. 2017. "Chemonaïveté in Inoperable Malignant Bowel Obstruction" Current Oncology 24, no. 1: 75. https://doi.org/10.3747/co.24.3362

Article Metrics

Back to TopTop